US FDA Forced To Rip Up, Start Biosimilar First Interchangeable Exclusivity Guidance Again

 
• By Derrick Gingery
  
New fact patterns forced the FDA to restart first interchangeable biosimilar exclusivity guidance development. (Shutterstock)

More from Regulation

More from Products